RayKnowChina Research Map
Shortlist

RecruitingLymphomaPhase 2

Registered title, quoted from ClinicalTrials.gov

PD-1 Antibody-based Therapy With Concurrent RT for Early-stage NKTCL

An open trial on lymphoma, registered on ClinicalTrials.gov. Led by Ruijin Hospital; 0 other hospitals on this site are listed as study sites.

Status, phase and start date as registered on ClinicalTrials.gov on 18 Nov 2026; the registry may have changed since. Whether someone can take part is decided by the study team. Not medical advice.

The study team’s contact details are on the registry record. This site does not pass on enquiries.

Hospitals in mainland China listed for this trial 1

Hospitals on this site that the registry record names as lead sponsor or study site, where the site is open. Lead sponsor first, then study sites A–Z.

  1. Lead sponsorRuijin Hospital上海交通大学医学院附属瑞金医院ShanghaiHospital page

The record may name more sites, including outside mainland China, and sites can open or close during a trial. Full list of sites on ClinicalTrials.gov

Source: ClinicalTrials.gov record NCT07380984, read on 18 Nov 2026; hospital names matched to this site’s hospital list. How names are matched

Checklist for this trial 6

Only the points this trial’s record answers definitely: the registered age and sex, and criteria lines that state a number, score, stage or named test, quoted word for word. Tick a point once it has been compared with the medical records.

Show the checklist (6 points)Hide the checklist
  1. 18 years to Not stated; sex: all

    Registered eligibility fields

  2. At least one measurable/evaluable disease site confirmed by diagnostic biopsy prior to the initiation of treatment.

    Inclusion criterion 6

  3. Prior treatment with anti-PD-1, anti-PD-L1, or anti-PD-L2 agents.

    Exclusion criterion 11

    Use of systemic immunosuppressive agents within 2 weeks prior to the initiation of study treatment, or planned use of such agents during the study period, including cyclophosphamide, azathioprine, methotrexate, thalidomide, and anti-tumor necrosis factor (anti-TNF) drugs.

    Exclusion criterion 13

  4. Eastern Cooperative Oncology Group (ECOG) performance status score of 0-2.

    Inclusion criterion 7

  5. Absolute neutrophil count (ANC) > 1,000/μL

    Inclusion criterion 11

    Platelet count > 50,000/μL

    Inclusion criterion 12

    Hemoglobin > 9 g/dL

    Inclusion criterion 13

    Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) < 3× upper limit of normal (ULN)

    Inclusion criterion 14

    Serum total bilirubin < 1.5 × ULN (patients with Gilbert's syndrome are eligible)

    Inclusion criterion 15

    Serum creatinine < 2 × ULN or creatinine clearance > 50 mL/min

    Inclusion criterion 16

  6. A history of autoimmune disease requiring systemic treatment (i.e., with disease-modifying antirheumatic drugs, corticosteroids, or immunosuppressants) within the past 2 years, including but not limited to myasthenia gravis, myositis, autoimmune hepatitis, systemic lupus erythematosus, rheumatoid arthritis, inflammatory bowel disease, antiphospholipid antibody-associated vasculopathy, granulomatosis with polyangiitis (Wegener's), Sjögren's syndrome, Guillain-Barré syndrome, multiple sclerosis, vasculitis, or glomerulonephritis.

    Exclusion criterion 3

    A history of other invasive malignancies within the past 3 years that has not been treated with curative intent or is currently receiving anticancer therapy (including hormonal therapy for breast or prostate cancer).

    Exclusion criterion 4

    Positive results for HBsAg, HCV, or HIV; HBV seropositivity is permitted only if HBV DNA < 1000 IU/mL;

    Exclusion criterion 8

Ticks stay on this page; they are not saved or sent. Meeting every point is not enough: the study team decides after its own screening. Lines that need the team’s judgement, such as “sufficient organ function”, are not in this list; they are in the full criteria below. Not stated definitely in this record: stage or severity, as the trial defines it; scans and measurable lesions; pregnancy, breastfeeding and contraception.

Questions to ask the study team

Picked from the record by fixed keyword rules (not by AI, not checked by hand) and quoted from ClinicalTrials.gov, NCT07380984, read on 10 Nov 2026.

Registered criteria

Quoted as registered on ClinicalTrials.gov, in English, read on 10 Nov 2026. This site has not checked, shortened or translated them. Meeting the written criteria is not enough: the study team decides after its own screening.

Inclusion Criteria:

  • The subject has histopathologically confirmed extranodal NK/T-cell lymphoma, nasal type (according to the 2022 WHO classification).
  • No prior history of anti-lymphoma therapy.
  • Age ≥ 18 years.
  • Life expectancy > 3 months.
  • Ann Arbor stage I-II.
  • At least one measurable/evaluable disease site confirmed by diagnostic biopsy prior to the initiation of treatment.
  • Eastern Cooperative Oncology Group (ECOG) performance status score of 0-2.
  • Signed informed consent form (ICF).
  • Willingness and ability to comply with the study protocol.
  • Sufficient bone marrow, hepatic, and renal function, defined as:
  • Absolute neutrophil count (ANC) > 1,000/μL
  • Platelet count > 50,000/μL
  • Hemoglobin > 9 g/dL
  • Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) < 3× upper limit of normal (ULN)
  • Serum total bilirubin < 1.5 × ULN (patients with Gilbert's syndrome are eligible)
  • Serum creatinine < 2 × ULN or creatinine clearance > 50 mL/min
  • Availability of tumor tissue samples (preferably fresh tissue; archived tissue samples are acceptable).
  • For women of childbearing potential, agreement to use adequate contraception to avoid pregnancy during the study treatment period.
  • For male, agreement to remain abstinent or use a barrier method of contraception.

Exclusion Criteria:

  • Advanced-stage disease (Ann Arbor Stage III-IV).
  • Nonnasal-type NKTCL.
  • A history of autoimmune disease requiring systemic treatment (i.e., with disease-modifying antirheumatic drugs, corticosteroids, or immunosuppressants) within the past 2 years, including but not limited to myasthenia gravis, myositis, autoimmune hepatitis, systemic lupus erythematosus, rheumatoid arthritis, inflammatory bowel disease, antiphospholipid antibody-associated vasculopathy, granulomatosis with polyangiitis (Wegener's), Sjögren's syndrome, Guillain-Barré syndrome, multiple sclerosis, vasculitis, or glomerulonephritis.

The following conditions are permissible for enrollment: patients with autoimmune hypothyroidism or type 1 diabetes receiving stable treatment; hormone replacement therapy (e.g., levothyroxine, insulin, or supplementation with physiological hormones for adrenal or pituitary insufficiency) is not considered systemic therapy and is allowed.

  • A history of other invasive malignancies within the past 3 years that has not been treated with curative intent or is currently receiving anticancer therapy (including hormonal therapy for breast or prostate cancer).
  • A history of (non-infectious) pneumonia requiring corticosteroid therapy; or clinical evidence of interstitial lung disease or active, non-infectious pneumonia.
  • Active infections requiring systemic treatment, including:
  • A known history of active tuberculosis;
  • Positive results for HBsAg, HCV, or HIV; HBV seropositivity is permitted only if HBV DNA < 1000 IU/mL;
  • Active viral infections other than hepatitis B and C (e.g., herpes zoster).
  • Severe cardiovascular disease, including myocardial infarction, unstable arrhythmia, or unstable angina occurring within the past 3 months.
  • Prior treatment with anti-PD-1, anti-PD-L1, or anti-PD-L2 agents.
  • Administration of live-attenuated vaccines within 4 weeks prior to the initiation of study treatment; patients are prohibited from receiving live-attenuated vaccines during the study period, including influenza vaccines.
  • Use of systemic immunosuppressive agents within 2 weeks prior to the initiation of study treatment, or planned use of such agents during the study period, including cyclophosphamide, azathioprine, methotrexate, thalidomide, and anti-tumor necrosis factor (anti-TNF) drugs.
  • Evidence of central nervous system involvement.
  • A history of allogeneic tissue/solid organ transplantation.
  • A history of severe hypersensitivity reactions (Grade ≥ 3) to PD-1 monoclonal antibodies and/or their excipients, or to gorlitinib and/or its excipients.
  • Any other factors judged by the investigator to potentially affect compliance with the study protocol.

Quoted from ClinicalTrials.gov, NCT07380984, participation criteria. Read on 10 Nov 2026.

Where this information comes from

The registry record

ClinicalTrials.gov (US National Library of Medicine), record NCT07380984, read on 18 Nov 2026. A trial has a page here while its overall status is recruiting, not yet recruiting or enrolling by invitation and at least one listed hospital’s site is open. Trials registered only in China’s own registry (ChiCTR) are not included.

Diseases and hospitals

The trial is listed under a disease when this site’s ClinicalTrials.gov search for that disease in China returns it. Sponsor and site names in the record are matched to this site’s hospital list (ROR identifiers, checked aliases). Definitions

What is left out

Names of investigators and contact persons in the record, and anything not in the record. The title and criteria are quoted from the record.

Suggest a correctionClinicalTrials.gov NCT07380984